ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation), the largest clinical trial ever performed in patients with type 2 diabetes worldwide, demonstrated that intensive blood glucose control using Diamicron MR (gliclazide modified release) and other drugs as required, protects patients against serious complications of the disease. In more details, the major findings of ADVANCE show that intensive glucose control strategy using Diamicron MR and other drugs:
– Safely controlled blood glucose to a mean HbA1c level of 6.5%
– Significantly reduced by 10% the overall risk of serious diabetes complications, with a 21% reduction in kidney disease and 30% reduction in the development of macroalbuminuria, a well established marker of increased cardiovascular risk.
– Achieved a positive trend towards a reduction in the risk of cardiovascular death.
New data from ADVANCE, were presented at the last International Diabetes Federation (IDF) Congress. It shows that the efficacy and safety of intensive blood glucose control using Diamicron MR is maintained across a broad range of patients in different clinical settings: irrespective of age, duration of diabetes, sex, body mass index, or HbA1C at study entry, and also irrespective of initial glucose lowering treatment.